Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc2206274 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of liposomal amphotericin B in treating fungal meningitis in AIDS Patients: A review article.
Egypt J Immunol
January 2025
Department of Microbiology and Infection Prevention and Control Unit, Theodor Bilharz Research Institute, Giza 12411, Egypt.
Cryptococcal meningitis is an alarming fungal infection that usually affects the meninges surrounding the brain and spinal cord. The causative organism is Cryptococcus neoformans. Although this infection can occur in normal individuals, it is more often seen in patients with human immunodeficiency virus/acquired immunodeficiency syndrome.
View Article and Find Full Text PDFUsing single-dose liposomal amphotericin B for cryptococcal meningitis induction therapy: nurse pearls and practical perspectives.
Wellcome Open Res
October 2024
Department of Research, Infectious Diseases Institute, College of Health Sciences, Makerere University, Mulago, Kampala, Uganda.
Article Synopsis
- A study in Uganda highlights the use of single-dose liposomal amphotericin B (AmBisome) for treating HIV-associated cryptococcal meningitis, showcasing the nursing perspective in its administration.
- The research details the preparation and administration process, revealing that single-dose AmBisome requires significantly less nursing time than daily doses of conventional amphotericin B.
- The findings suggest that single-dose liposomal amphotericin B results in fewer side effects and complications, ultimately improving nursing care efficiency in resource-limited settings.
Treatment Outcomes of Single-Dose Liposomal Amphotericin B-Treated Visceral Leishmaniasis Patients and Factors Affecting Outcome in Bihar, India.
Am J Trop Med Hyg
December 2024
Indian Council of Medical Research (ICMR)-Rajendra Memorial Research Institute of Medical Sciences (RMRIMS), Patna, India.
Article Synopsis
- A study was conducted to evaluate the treatment outcomes of single-dose liposomal amphotericin B for visceral leishmaniasis (VL) and post-kala-azar dermal leishmaniasis (PKDL), involving 527 cases, primarily VL.
- The cure rate for VL was found to be 95%, with significant differences in treatment success between genders and age groups; males had higher success rates than females, while younger patients (≤23 years) also fared better.
- The study highlighted that PKDL patients treated with this drug had a significantly shorter duration of disease development compared to those who received alternative treatments, emphasizing the need for ongoing monitoring of treatment strategies.
Development and deployment of a solid oral amphotericin B dosage form to treat visceral leishmaniasis within a pediatric population.
PLoS Negl Trop Dis
September 2024
Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Visceral leishmaniasis (VL) is a severe and potentially fatal infection, with over 90% of reported cases occurring in East African countries including Chad, Djibouti, Eritrea, Ethiopia, Kenya, Somalia, South Sudan, Sudan, and Uganda, affecting mainly impoverished individuals, and creating a significant economic burden. Currently, the intravenous single-dose liposomal amphotericin B is the first choice for the treatment of VL. Recently, WHO and DNDi have suggested a combination of intravenous liposomal amphotericin B and oral miltefosine as a potential approach to treat VL.
View Article and Find Full Text PDFAll hands on Dec: Treating cryptococcosis with dectin decorated liposomes loaded with antifungals.
iScience
July 2024
Department of Plant Biology, University of Georgia, Athens, GA 30602, USA.
Systemic cryptococcosis is often fatal even with the current antifungal therapy and there is no vaccine available. Induction therapy with amphotericin B (AmB) is essential for its treatment, which can be either in the form of AmB deoxycholate at 1 mg/kg/day for 7 days or a single dose of liposomal AmB (AmB-LLs) at 10 mg/kg, both in combination with flucytosine. AmB is highly toxic and it is imperative to further increase its efficacy without increasing its toxicity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!